What is the impact of sulfonylureas for treatment of type 2 diabetes mellitus (DM) on cardiovascular mortality rates?

Updated: Sep 27, 2021
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print

One study exonerated the sulfonylurea group of oral agents as the chief cause of cardiovascular death in diabetic patients admitted with acute myocardial infarction. However, even though sulfonylureas were safer in general, within the group, the use of glyburide was associated with highest mortality (7.5%) compared with other sulfonylureas, such as gliclazide and glimepiride (2.7%). [188] This raises an important concern about whether the use of glyburide should be avoided.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!